Plain-English translation of NCT06840886 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new cancer medication called in adults whose solid tumors have stopped responding to standard treatments. The study will first test the medication alone at increasing dose levels to find the safest and most effective dose, then test it in combination with chemotherapy drugs. Researchers want to understand how the medication works in the body, what side effects it causes, and whether it can slow or stop tumor growth.
Many patients with advanced cancers run out of standard treatment options, and their cancers stop responding to existing therapies. This medication targets a protein called CD24 that may help cancer cells hide from the immune system, so this trial is exploring whether blocking that protein could be a new way to fight these hard-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
Participants in the first part of the trial will receive increasing doses of the medication as a single treatment and undergo blood tests and imaging scans to monitor safety and how the medication affects their tumors. Once researchers determine a safe dose, the second part of the trial will test this medication combined with one of several standard chemotherapy drugs, with participants enrolling into groups based on their cancer type (ovarian, endometrial, or bile duct cancer). Throughout the trial, you would have regular clinic visits for blood draws, scans, and physical exams to track how you're responding and watch for side effects.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
United States